Roshawn Blunt, Brand Insights Contributor, Managing Director of 1798, a Fingerpaint company

Why it’s important to integrate patient assistance programs for cell and gene therapies into the overall clinical development plan.

New drug launches face more marketplace scrutiny today than a decade ago. Brand success requires not only communicating the clinical value to providers and patients, but also demonstrating the cost-effectiveness to payers in a real-world setting.